All peptides
CardiovascularInvestigational

Urocortin 1

Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Urocortin 1 is a 40-amino acid peptide belonging to the corticotropin-releasing factor (CRF) family. It binds to both CRF receptor 1 and CRF receptor 2 with high affinity, mediating diverse cardiovascular effects including vasodilation, positive inotropy, and cardioprotection.

Mechanism of Action

The peptide has demonstrated beneficial hemodynamic properties and anti-inflammatory actions in preclinical models of heart failure and ischemia-reperfusion injury.

Research Summary & Key Findings

Early phase clinical trials have evaluated urocortin 1 infusion in heart failure patients, demonstrating hemodynamic improvements including increased cardiac output and reduced systemic vascular resistance. However, no large-scale efficacy trials have been completed, and development for cardiovascular indications remains investigational.

Clinical Status

Investigational

Urocortin 1 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Intravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Cardiovascular

Start Your Consultation

Get an AI-proposed Urocortin 1 protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Urocortin 1.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.